Skip to content

Replimune Group REPL Enterprise value

Enterprise value at other companies

Amgen logo
AmgenAMGN
$246.43B+9.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$1B+982%
Immunome logo
ImmunomeIMNM
$1.9B+470%
CG Oncology logo
CG OncologyCGON
$5.69B+212%
Erasca, Inc. logo
Erasca, Inc.ERAS
$5.03B+1,265%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's enterprise value?
Replimune Group (REPL) reported enterprise value of $717.02M in Q4 2025.
How has Replimune Group's enterprise value changed year-over-year?
Replimune Group's enterprise value decreased by 14.3% year-over-year, from $836.81M to $717.02M.
What is the long-term trend for Replimune Group's enterprise value?
Over 4 years (2021 to 2025), Replimune Group's enterprise value has grown at a -13.5% compound annual growth rate (CAGR), from $1.28B to $717.04M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.